Compare HLX & ALVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HLX | ALVO |
|---|---|---|
| Founded | 1979 | 2013 |
| Country | United States | Luxembourg |
| Employees | N/A | 1460 |
| Industry | Oilfield Services/Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.1B |
| IPO Year | 1996 | N/A |
| Metric | HLX | ALVO |
|---|---|---|
| Price | $8.64 | $3.92 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $11.50 | $8.00 |
| AVG Volume (30 Days) | ★ 1.3M | 1.0M |
| Earning Date | 04-22-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $876,561,000.00 | N/A |
| Revenue This Year | $2.05 | $13.28 |
| Revenue Next Year | $5.46 | $18.63 |
| P/E Ratio | ★ N/A | $18.20 |
| Revenue Growth | ★ 3.60 | N/A |
| 52 Week Low | $5.52 | $2.94 |
| 52 Week High | $10.75 | $9.94 |
| Indicator | HLX | ALVO |
|---|---|---|
| Relative Strength Index (RSI) | 34.57 | 55.06 |
| Support Level | $8.58 | $3.09 |
| Resistance Level | $10.54 | $4.17 |
| Average True Range (ATR) | 0.34 | 0.32 |
| MACD | -0.09 | 0.03 |
| Stochastic Oscillator | 14.08 | 59.39 |
Helix Energy Solutions Group Inc is an offshore energy services company. It provides specialty services to the offshore energy industry, with an emphasis on well intervention and robotics operations. Helix provides services in deep water in the Gulf of Mexico, Brazil, the North Sea, Asia Pacific and West Africa regions. It has four segments: Well Intervention, Robotics, Shallow Water Abandonment and Production Facilities. The Well Intervention segment includes vessels and equipment used to perform well intervention services in the Gulf of Mexico, the North Sea and Brazil. It derives the majority of its revenue from the U.S., and it also has its presence in North Sea, Brazil, Asia Pacific, West Africa, and Other.
Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients globally. Its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases. The company's commercialized products incldue AVT02, AVT03, AVT04, AVT05, and AVT06. Its pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer. Geographically, the company generates the majority of revenue from Europe, and the rest from the USA and the rest of the world.